Case Studies
Case Studies
The Virtuoso epigenomics platform, by ClearNote Health, measures active disease biology from drug discovery through development, including dynamic insights into therapy response and resistance — all through a simple blood draw.
CASE STUDY 1:
Virtuoso Provides Insights into Underlying Pancreatic Cancer Biology in Plasma Profiles
– 5hmC analysis identifies gene activation downstream of KRAS activating and p53 inactivating mutations in the plasma of patients with pancreatic cancer.
Ref: Guler et al Nature Communications 2020
CASE STUDY 2:
Non-Invasive Prediction & Monitoring of Immunotherapy Response in Lung Cancer
– Captures distinct changes in the plasma-derived cfDNA 5hmC profiles after anti-PD1 treatment in responders and non-responders
– Observed responses early, with the first cycle of treatment.
Ref: Guler et al JITC 2024
CASE STUDY 3:
Virtuoso Defines Prognostic Genes for Prostate Cancer mCRPC ARSI Treatment in Plasma-derived cfDNA
– Prognostic genes, previously identified through tissue RNA and protein analysis, are captured by 5hmC analysis in plasma.
Ref: Sjostrom et al Cancer Res. 2022
Speak With Our Team
”Traditional drug development processes are challenged by limited tissue availability and lack of tools that can capture tumor evolution and biology that is driven by non-genetic mechanisms. Learn how Virtuoso overcomes these challenges for BioPharma Partners.”
Ceyda Coruh,
Senior Scientist, ClearNote Health
